Drug blocks lethal motor-neuron disease in mice

Spinal muscular atrophy (SMA) is an inherited motor-neuron disease that, in its most severe form, leads to death before 2 years of age and for which there is no treatment. It is caused by mutations in the gene SMN1 that prevent SMN1 producing the protein SMN. A second gene, SMN2, can also produce SMN, but it is much less efficient than SMN1 at doing so. Developing ways to increase SMN production by SMN2 are therefore of potential therapeutic interest.

In a study that appears online on February 22 in advance of publication in the March print issue of the Journal of Clinical Investigation, Charlotte Sumner and colleagues from the NIH show that in a mouse model of SMA a drug known as trichostatin A (TSA) can increase the amount of SMN2 produced SMN in both neural tissues and muscles (the tissues that are affected in humans with SMA). Importantly, daily administration of TSA (which is a hydroxamic acid HDAC inhibitor) to mice already showing signs of SMA-like disease improved their chances of survival and attenuated their disease symptoms. This study therefore provides support for the idea that hydroxamic acid HDAC inhibitors should be developed for the treatment of individuals with SMA.


Contact: Karen Honey
Journal of Clinical Investigation

Page: 1

Related biology news :

1. Molecule blocks gene, sheds light on liver cancer
2. MIT researchers probe bones tiny building blocks
3. Blood sugars manufacture limited by building blocks supply
4. Yale chemists show that nature could have used different protein building blocks
5. Sentry enzyme blocks two paths to Parkinsons disease
6. Researchers discover surprising drug that blocks malaria
7. New drug blocks influenza, including bird flu virus
8. Cigarette smoke blocks cell repair mechanism, University of Florida study shows
9. LEGO-Like building blocks to halt cell growth wins Hebrew University prize
10. Patent awarded for LSUHSC-developed peptide that blocks lethal toxins of anthrax
11. Study shows drug blocks breast cancer migration to bone

Post Your Comments:

(Date:6/25/2020)... ... June 24, 2020 , ... ... and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm ... XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study ...
(Date:6/23/2020)... England (PRWEB) , ... June 23, 2020 , ... ... Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of ... project to support testing operations in the fight against the COVID-19 pandemic in ...
(Date:6/23/2020)... ... June 23, 2020 , ... Rigaku Corporation , a ... in a series of TOPIQ webinars, which will cover the Transferable Aspherical Atom ... in response to social distancing measures that resulted in postponements and cancelations of ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/31/2020)... ... 2020 , ... The SDX® Respiratory Gating System , ... reached its 20th anniversary of worldwide use. Introduced in the US over the ... University of Pennsylvania, University of Michigan, University of Maryland, University of California San ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
Breaking Biology Technology:
Cached News: